New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.

Abstract:

BACKGROUND:Anti-tumour necrosis factor α (anti-TNF) agents have been implicated in drug-induced liver injury. There is minimal data on this occurrence in inflammatory bowel disease (IBD) patients. AIM:To identify the characteristics of liver enzyme elevations following anti-TNF therapy initiation in IBD. METHODS:A retrospective cohort of patients initiating anti-TNF therapy were analysed for new onset alanine transaminase (ALT) elevation (≥60 U/L). We collected data on natural history, outcomes and patient characteristics compared with controls with persistent normal liver enzymes. Likelihood of causal association was assessed using the RUCAM score. RESULTS:From 1753 patients initiating an anti-TNF (1170 infliximab, 575 adalimumab, 8 certolizumab), 102 (6%) developed new onset ALT elevation. In 54 (53%), this could be linked to an alternate aetiology. Among those with idiopathic ALT elevations, the median time to ALT elevation from anti-TNF initiation was 18 weeks and median peak ALT was 96 U/L. Six underwent liver biopsy, all demonstrating hepatitis with autoimmune features. Compared to controls, cases were on a lower dose of infliximab (5.7 vs. 6.7 mg/kg, P = 0.02) but were otherwise similar in body mass index, sex and age. On follow-up, 34 continued the anti-TNF, 14 stopped therapy and 4 initiated steroids. Most (85%) normalised their LFTs after a median of 17 weeks including 28 (82%) of those who continued anti-TNF therapy. Ten patients were transitioned to a second anti-TNF without recurrence. CONCLUSIONS:ALT elevations occurred in 6% of IBD patients initiating anti-TNF therapy. Most idiopathic elevations were mild, transient and resolved despite therapy continuation.

journal_name

Aliment Pharmacol Ther

authors

Shelton E,Chaudrey K,Sauk J,Khalili H,Masia R,Nguyen DD,Yajnik V,Ananthakrishnan AN

doi

10.1111/apt.13159

subject

Has Abstract

pub_date

2015-05-01 00:00:00

pages

972-9

issue

10

eissn

0269-2813

issn

1365-2036

journal_volume

41

pub_type

杂志文章
  • An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively.

    abstract:BACKGROUND:The combination of omeprazole and amoxycillin has demonstrated effectiveness with very few side-effects in the treatment of H. pylori infection, however cure rates have varied widely. The present study addresses the question as to the extent to which the cure rate of H. pylori infection depends on the size o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1997.140316000.x

    authors: Miehlke S,Mannes GA,Lehn N,Hele C,Stolte M,Bayerdörffer E

    更新日期:1997-04-01 00:00:00

  • Occupational asbestos exposure and digestive cancers - a cohort study.

    abstract:BACKGROUND:Although the role of asbestos in the genesis of mesothelioma and primary bronchopulmonary cancers has been established, results from studies focusing on the relationship between occupational exposure to asbestos and digestive cancer remain contradictory. AIM:To determine whether occupational asbestos exposu...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.04050.x

    authors: Clin B,Morlais F,Dubois B,Guizard AV,Desoubeaux N,Marquignon MF,Raffaelli C,Paris C,Galateau-Salle F,Launoy G,Letourneux M

    更新日期:2009-08-15 00:00:00

  • A non-toxic analogue of a coeliac-activating gliadin peptide: a basis for immunomodulation?

    abstract:BACKGROUND:A-gliadin residues 31-49 (peptide A) binds to HLA-DQ2 and is toxic to coeliac small bowel. Analogues of this peptide, which bind to DQ2 molecules but are non-toxic, may be a potential route to inducing tolerance to gliadin in patients with coeliac disease. METHODS:Toxicity was investigated with small bowel ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00512.x

    authors: Biagi F,Ellis HJ,Parnell ND,Shidrawi RG,Thomas PD,O'Reilly N,Corazza GR,Ciclitira PJ

    更新日期:1999-07-01 00:00:00

  • Use of acid-suppressive therapy before anti-reflux surgery in 2922 patients: a nationwide register-based study in Denmark.

    abstract:BACKGROUND:Guidelines recommend that patients with gastro-oesophageal reflux disease are adequately treated with acid-suppressive therapy before undergoing anti-reflux surgery. Little is known of the use of acid-suppressive drugs before anti-reflux surgery. AIM:To determine the use of proton pump inhibitors and H2 -re...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13230

    authors: Lødrup A,Pottegård A,Hallas J,Bytzer P

    更新日期:2015-07-01 00:00:00

  • Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome.

    abstract:BACKGROUND:Gut microflora-mucosal interactions may be involved in the pathogenesis of irritable bowel syndrome (IBS). AIM:To investigate the efficacy of a novel prebiotic trans-galactooligosaccharide in changing the colonic microflora and improve the symptoms in IBS sufferers. METHODS:In all, 44 patients with Rome II...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2008.03911.x

    authors: Silk DB,Davis A,Vulevic J,Tzortzis G,Gibson GR

    更新日期:2009-03-01 00:00:00

  • The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study.

    abstract:BACKGROUND:Uninvestigated dyspepsia is common in family practice. The prevalence of clinically significant upper gastrointestinal findings (CSFs) in adult uninvestigated dyspepsia patients, and their predictability based on history, is unknown. METHODS:Prompt endoscopy was performed within 10 days of referral, in 1040...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2003.01646.x

    authors: Thomson AB,Barkun AN,Armstrong D,Chiba N,White RJ,Daniels S,Escobedo S,Chakraborty B,Sinclair P,Van Zanten SJ

    更新日期:2003-06-15 00:00:00

  • The effects of propranolol on hepatic encephalopathy in patients with cirrhosis and portal hypertension.

    abstract::Beta adrenoreceptor blocking drugs have been used for the prevention of haemorrhage from oesophageal varices. However, it is possible that these agents, by virtue of their effects on hepatic blood flow, may impair liver function and precipitate hepatic encephalopathy. We have therefore studied the effect of the beta b...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1988.tb00681.x

    authors: Dunk AA,Moore J,Symon A,Dickie A,Sinclair TS,Mowat NA,Brunt PW

    更新日期:1988-04-01 00:00:00

  • Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.

    abstract:BACKGROUND:Attainment of intragastric pH < 6.0 may require high-dose continuously infused proton pump therapy. AIM:To assess the pharmacokinetic and pharmacodynamic dose-responses of continuous infusion regimens of lansoprazole. METHODS:Healthy adult subjects were assigned to lansoprazole 60-mg intravenous bolus, fol...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2006.02849.x

    authors: Howden CW,Metz DC,Hunt B,Vakily M,Kukulka M,Amer F,Samra N

    更新日期:2006-04-01 00:00:00

  • Gastric carcinoids after long-term use of a proton pump inhibitor.

    abstract:BACKGROUND:Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion and give hypergastrinemia secondary to gastric hypoacidity. PPI treatment therefore induces enterochromaffin-like (ECL) cell hyperplasia. Long-term hypergastrinemia in rodents and man also leads to ECL cell neoplasia. Whether long-...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12012

    authors: Jianu CS,Fossmark R,Viset T,Qvigstad G,Sørdal O,Mårvik R,Waldum HL

    更新日期:2012-10-01 00:00:00

  • Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders.

    abstract:BACKGROUND:Fructose malabsorption, lactose malabsorption and an early rise in breath hydrogen after lactulose (ERBHAL) may play roles in induction of symptoms in gastrointestinal conditions. AIM:To compare prevalence and interactions of fructose malabsorption, lactose malabsorption and ERBHAL among healthy subjects an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.04018.x

    authors: Barrett JS,Irving PM,Shepherd SJ,Muir JG,Gibson PR

    更新日期:2009-07-01 00:00:00

  • Activity of metronidazole, azithromycin and three benzimidazoles on Giardia lamblia growth and attachment to a human intestinal cell line.

    abstract:BACKGROUND:Attachment of Giardia lamblia trophozoites to enterocytes is essential for colonization of the small intestine and is considered a prerequisite for Giardia-induced enterocyte damage. Inhibition of attachment may therefore have therapeutic potential. METHODS:Enterocyte-like differentiated Caco-2 cells were u...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1994.tb00277.x

    authors: Katelaris PH,Naeem A,Farthing MJ

    更新日期:1994-04-01 00:00:00

  • Rifaximin in the treatment of recurrent Clostridium difficile infection.

    abstract:BACKGROUND:Clostridium difficile can cause severe antibiotic-associated colitis. Conventional treatments with metronidazole and vancomycin improve symptoms, but after discontinuation of treatment, C. difficile infection (CDI) recurs in a number of patients. Rifaximin is a rifamycin-based non-systemic antibiotic that ha...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12111

    authors: Mattila E,Arkkila P,Mattila PS,Tarkka E,Tissari P,Anttila VJ

    更新日期:2013-01-01 00:00:00

  • Personal view: cost and benefit of medical rituals in gastroenterology.

    abstract:BACKGROUND:Unable to resolve a medical problem, gastroenterologists occasionally choose an ineffectual intervention instead. The elusive path to effectual management becomes substituted with an ineffectual but readily available medical ritual. The term 'ritual' refers to the utilization of an ineffectual intervention w...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2004.02252.x

    authors: Sonnenberg A

    更新日期:2004-11-01 00:00:00

  • Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.

    abstract:BACKGROUND:HCV-TARGET is a longitudinal observational study of chronic hepatitis C virus (HCV) patients treated with direct-acting anti-viral agents (DAAs) in a US consortium of 90 academic and community medical centres. AIM:To assess utilisation of response-guided therapy (RGT) and sustained virological response (SVR...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/apt.13095

    authors: Sterling RK,Kuo A,Rustgi VK,Sulkowski MS,Stewart TG,Fenkel JM,El-Genaidi H,Mah'moud MA,Abraham GM,Stewart PW,Akushevich L,Nelson DR,Fried MW,Di Bisceglie AM

    更新日期:2015-04-01 00:00:00

  • Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome.

    abstract:BACKGROUND:ONO-2952 is a novel and selective inhibitor of translocator protein 18 kDa that reduces stress-induced defecation and visceral hyperalgesia in rat models. AIM:To evaluate the efficacy and safety of ONO-2952 in females with irritable bowel syndrome with diarrhoea in an exploratory proof-of-concept study. ME...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/apt.13839

    authors: Whitehead WE,Duffy K,Sharpe J,Nabata T,Bruce M

    更新日期:2017-01-01 00:00:00

  • Systematic review: prevention of travellers' diarrhoea.

    abstract:BACKGROUND:Renewed interest in the use of antibiotics to prevent travellers' diarrhoea has occurred with the availability of non-absorbed (<0.4%) rifaximin, and with evidence that a subgroup of travellers with diarrhoea have progression of their illnesses to postinfectious irritable bowel syndrome. AIM:To summarize re...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2008.03647.x

    authors: DuPont HL

    更新日期:2008-05-01 00:00:00

  • Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy.

    abstract:BACKGROUND:Recent evidence found probiotics could inhibit Helicobacter pylori colonization from both in vitro and in vivo studies. AIM:To systematically evaluate whether adding probiotics to anti-H. pylori regimens could improve eradication rates and reduce side effects during anti-H. pylori treatment. METHODS:Eligib...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/j.1365-2036.2006.03179.x

    authors: Tong JL,Ran ZH,Shen J,Zhang CX,Xiao SD

    更新日期:2007-01-15 00:00:00

  • Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.

    abstract:BACKGROUND:Therapeutic drug monitoring is a powerful strategy known to improve the clinical outcomes and to optimise the healthcare resources in the treatment of autoimmune diseases. Currently, most of the methods commercially available for the quantification of infliximab (IFX) are ELISA-based, with a turnaround time ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13757

    authors: Afonso J,Lopes S,Gonçalves R,Caldeira P,Lago P,Tavares de Sousa H,Ramos J,Gonçalves AR,Ministro P,Rosa I,Vieira AI,Dias CC,Magro F,Portuguese IBD Study Group (GEDII).

    更新日期:2016-10-01 00:00:00

  • The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.

    abstract:BACKGROUND:In vitro studies suggest interactions between mesalazine (mesalamine) and thiopurines by thiopurine S-methyltransferase (TPMT) inhibition, influencing the balance of hepatotoxic 6-methylmercaptopurine ribonucleotide and immunosuppressive tioguanine (thioguanine) metabolites. AIM:To examine the in vivo pharm...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.2005.02630.x

    authors: Gilissen LP,Bierau J,Derijks LJ,Bos LP,Hooymans PM,van Gennip A,Stockbrügger RW,Engels LG

    更新日期:2005-10-01 00:00:00

  • How accurate is the determination of blood in gastric juice? Comparison of peroxidase and porphyrin methods.

    abstract:BACKGROUND:Mucosal bleeding is frequently used as a measure of gastric mucosal integrity. We compared the orthotolidine method for quantifying haemoglobin in gastric juice with a method based on measurement of fluorescent porphyrins extracted from haem. We also investigated whether acid or pepsin had a deleterious effe...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.0953-0673.1996.00333.x

    authors: Woods KL,Kiefe C,Graham DY

    更新日期:1996-06-01 00:00:00

  • An analysis of the placebo effect in Crohn's disease over time.

    abstract:BACKGROUND:Randomized, placebo controlled trials are used to assess the efficacy of therapies for Crohn's disease. The placebo response and remission rates vary among studies. AIM:To analyse how the placebo response and remission rates in Crohn's trials have changed over time in the era of parenteral biologic therapie...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2009.04125.x

    authors: Gallahan WC,Case D,Bloomfeld RS

    更新日期:2010-01-01 00:00:00

  • Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease.

    abstract:BACKGROUND:Abnormal barrier function may be genetically determined in Crohn's disease. AIM:To examine the role of abnormal intestinal permeability in genetic predisposition in multiplex vs. sporadic Crohn's disease families. METHODS:Intestinal permeability was measured in patients, relatives and partners by means of ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2006.02916.x

    authors: D'Incà R,Annese V,di Leo V,Latiano A,Quaino V,Abazia C,Vettorato MG,Sturniolo GC

    更新日期:2006-05-15 00:00:00

  • Correlation of MAP kinases with COX-2 induction differs between MKN45 and HT29 cells.

    abstract:BACKGROUND:Mitogen-activated protein (MAP) kinases, including extracellular signal-regulated kinases (ERK),c-Jun NH2-terminal kinases (JNK) and p38 MAP kinase (p38 MAPK) are important intermediates of the signal-transduction pathway from the cell surface to the nucleus. Expression of cyclooxygenase (COX)-2, associated ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2004.01986.x

    authors: Tominaga K,Higuchi K,Sasaki E,Suto R,Watanabe T,Fujiwara Y,Oshitani N,Matsumoto T,Kim S,Iwao H,Arakawa T

    更新日期:2004-07-01 00:00:00

  • Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy.

    abstract:BACKGROUND:Current guidelines recommend the cessation of clopidogrel therapy 5 days and 7-10 days prior to colonoscopic polypectomy. Recent studies have advocated for continued clopidogrel as post-polypectomy bleeding (PPB) rates have been similar to those in the general population not on antithrombotic therapy. AIM:T...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.12292

    authors: Gandhi S,Narula N,Mosleh W,Marshall JK,Farkouh M

    更新日期:2013-05-01 00:00:00

  • Review article: defects in gall-bladder motor function--role in gallstone formation and recurrence.

    abstract::The pathogenesis of cholesterol gallstones is now recognized as a multifactorial process, including saturation of bile with cholesterol, destabilization of bile leading to cholesterol crystals and hypomotility permitting crystal growth, and agglomeration and retention of microstones which then grow to macroscopic gall...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2000.014s2032.x

    authors: Pauletzki J,Paumgartner G

    更新日期:2000-05-01 00:00:00

  • Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients.

    abstract:AIM:To perform a systematic review on the efficacy of intermittent and on-demand therapy with either histamine H2-receptor antagonists or proton pump inhibitors for patients with erosive oesophagitis or symptomatic heartburn. METHOD:We conducted randomized-controlled trials of non-continuous therapy in gastro-oesophag...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2005.02490.x

    authors: Zacny J,Zamakhshary M,Sketris I,Veldhuyzen van Zanten S

    更新日期:2005-06-01 00:00:00

  • Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.

    abstract:BACKGROUND:Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the intestine, which frequently require surgery for complications or failure of medical therapy. AIM:To seek evidence and provide direction for clinicians on optimal strategies to enable steroid free remission in inflammat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2008.03753.x

    authors: Panaccione R,Rutgeerts P,Sandborn WJ,Feagan B,Schreiber S,Ghosh S

    更新日期:2008-09-15 00:00:00

  • Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.

    abstract:BACKGROUND:In some cases, Helicobacter pylori infection persists even after three eradication treatments. AIM:To evaluate the efficacy of an empirical fourth-line rescue regimen with rifabutin in patients with three eradication failures. METHODS: DESIGN:Multicentre, prospective study. PATIENTS:In whom the following...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2012.05053.x

    authors: Gisbert JP,Castro-Fernandez M,Perez-Aisa A,Cosme A,Molina-Infante J,Rodrigo L,Modolell I,Cabriada JL,Gisbert JL,Lamas E,Marcos E,Calvet X

    更新日期:2012-04-01 00:00:00

  • Review article: from gastrin to gastro-oesophageal reflux disease--a century of acid suppression.

    abstract::To commemorate Edkins' discovery of gastrin in 1905, we review a century of progress in the physiology and pathobiology of gastrin and acid secretion especially as it pertains to clinical aspects of gastro-oesophageal reflux disease. Although initially ignored, Edkins' observations eventually led to the enthusiastic i...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.02817.x

    authors: Malfertheiner P,Fass R,Quigley EM,Modlin IM,Malagelada JR,Moss SF,Holtmann G,Goh KL,Katelaris P,Stanghellini V,Talley NJ,Tytgat GN,Wright NA

    更新日期:2006-03-15 00:00:00

  • Review article: can post-operative recurrence in Crohn's disease be prevented?

    abstract::The decision regarding prophylactic treatment after surgery in Crohn's disease (CD) requires a good estimation of the risk of recurrence. It is also important to consider the consequences of recurrence for the patient, and the risks and benefits of treatment, bearing in mind that it will be given over a long period. S...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.03055.x

    authors: Lémann M

    更新日期:2006-10-01 00:00:00